Cohera Medical Named One of the Region's Best Places to Work in 2012 Cohera Medical named one of the Pittsburgh region's Best Places to Work by the Pittsburgh Business Times for 2012
PITTSBURGH, Oct. 9, 2012 /PRNewswire/ -- Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical adhesives and sealants, today announced that it has been named one of the Pittsburgh region's 2012 Best Places to Work by the Pittsburgh Business Times.
The 2012 Best Places To Work program highlights the best employers in the Pittsburgh region from the perspective of the employees who complete online surveys about their work experience. The Pittsburgh Business Times has been presenting these awards since 2002.
"We believe our people are the most important asset and we are extremely proud to have been named a Best Place to Work in the Pittsburgh region," said Patrick Daly, President and Chief Executive Officer of Cohera Medical. "We have a culture that is second to none and a team of smart and passionate employees who create a very positive work environment. This honor is a testament to the commitment of every single person at Cohera."
Alan Robertson, publisher of the Pittsburgh Business Times, congratulated Cohera Medical on its achievement. "The future success of area businesses, and of the region as a whole, will be based on the quality of our workforce," said Robertson. "Any company that makes the Best Places to Work list is clearly a leader in workforce development."
Cohera Medical received CE Marking approval for TissuGlu® Surgical Adhesive and began selling product to hospitals and surgeons in Germany in September 2011. TissuGlu has been used successfully in over 600 various surgical procedures by leading surgeons. In the U.S., Cohera recently completed enrollment of a clinical trial for TissuGlu.
Currently, most patients who undergo abdominoplasty procedures and other large flap procedures require the insertion of drains to remove fluids that accumulate under the skin at the surgical site. In some cases, drainage is inadequate and the excess fluid accumulation (seroma) requires additional procedures for removal. TissuGlu adheres the tissue flap created during the procedure to the underlying tissue, helping to reduce the fluid that can accumulate in the space and ultimately reducing the time to drain removal. The use of TissuGlu may shorten the length of time that drains need to be in place, leading to a more comfortable recovery and a quicker return to normal activity for patients.
The honor will be formally announced at a luncheon at the Omni William Penn in downtown Pittsburgh on October 17, 2012. The Company will also be honored in a supplement produced by the Business Times.
About Cohera Medical
Cohera Medical, Inc.® is a leading innovator and developer of absorbable surgical adhesives and sealants. The Company's first product, TissuGlu® Surgical Adhesive, is an internal surgical adhesive for large flap surgeries, such as abdominoplasty (tummy tuck), that help eliminate or reduce fluid accumulation and the need for post surgical drains. TissuGlu's chemical composition is resorbable, non-toxic, forms a strong bond between tissue layers and allows for natural healing, which ultimately may enable faster recovery. TissuGlu has received CE Marking approval to be sold in the European Union (EU). Cohera Medical is also developing a unique and proprietary bowel sealant, and a strong adhesive for mesh fixation. Outside of the EU, TissuGlu and the other Cohera products are currently indicated for investigational use only and have not yet been approved for marketing by the Food and Drug Administration (FDA) in the U.S. or in any other market. For more information, visit www.coheramed.com.
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.
SOURCE Cohera Medical, Inc.